Skip to main content
    R

    Roivant Sciences Ltd (ROIV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $38.61
    -0.92 (-2.33%)

    Market Cap: $28.64B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Roivant Sciences Ltd (ROIV) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Roivant Sciences (ROIV) to earn -$1.47 per share in the fiscal year ending Mar 31, 2027, on revenue of $150.46M. Of 13 analysts, 11 rate the stock Buy or Strong Buy, 2 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 0 estimates for the fiscal year ending Mar 31, 2027 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.00, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 85% of the ratings.

    RatingAnalystsShare
    Strong Buy215.4%
    Buy969.2%
    Hold215.4%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    13

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a larger loss and revenue estimates rise 235.6%.

    Fiscal year ending Mar 31, 2027
    -$1.47
    EPS consensus, revenue $150.46M
    Fiscal year ending Mar 31, 2028
    -$1.61
    EPS consensus, revenue $504.93M

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Mar 31, 2027-$1.47-$1.89 to -$1.233$150.46M$114.96M to $171.62M3
    Mar 31, 2028-$1.61-$1.93 to -$1.273$504.93M$119.00M to $953.00M12

    Quarterly Estimates

    The EPS consensus rises from -$0.41 for the quarter ending Dec 31, 2026 to -$0.30 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$0.41-$0.50 to -$0.353$49.47M$37.93M to $63.49M3
    Mar 31, 2027-$0.30-$0.46 to -$0.1013$57.25M$6.60M to $101.85M13

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 1 upward and 6 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Mar 31, 202703
    Fiscal year ending Mar 31, 202810
    Quarter ending Dec 31, 202603

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Mar 31, 2027 has improved from -$1.58.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Mar 31, 2027-$1.47-$1.56-$1.58-$1.58-$1.58N/A
    Fiscal year ending Mar 31, 2028-$1.61-$1.39-$1.72-$1.72-$1.72N/A
    Quarter ending Dec 31, 2026-$0.41-$0.40-$0.41-$0.41-$0.41N/A

    Frequently Asked Questions About ROIV

    What is the ROIV stock forecast?

    Consensus analyst estimates put Roivant Sciences's EPS at -$1.47 for the fiscal year ending Mar 31, 2027, on revenue of $150.46M. The consensus rating from 13 analysts is Buy.

    How do analysts rate ROIV stock?

    Of 13 analysts covering Roivant Sciences, 2 rate it Strong Buy, 9 Buy, 2 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from ROIV next year?

    For the fiscal year ending Mar 31, 2027, the consensus EPS estimate is -$1.47, with estimates from -$1.89 to -$1.23 from 3 analysts. For the fiscal year ending Mar 31, 2028, the consensus EPS estimate is -$1.61, with estimates from -$1.93 to -$1.27 from 3 analysts.

    What revenue do analysts expect from Roivant Sciences next year?

    For the fiscal year ending Mar 31, 2027, the consensus revenue estimate is $150.46M, with estimates from $114.96M to $171.62M. For the fiscal year ending Mar 31, 2028, the consensus revenue estimate is $504.93M, with estimates from $119.00M to $953.00M.

    How many analysts cover ROIV?

    13 analysts rate Roivant Sciences stock, and 3 analysts estimate its EPS for the fiscal year ending Mar 31, 2027.